News

The FDA has launched a priority review of capivasertib and fulvestrant based on data from the phase 3 CAPItello-291 trial.

A new rule seeks to tackle plan member complaints.

Jaktinib is a novel JAK and AVCR1 inhibitor that showed activity in patients with myelofibrosis who were intolerant to or progressed on ruxolitinib.

The FDA has launched a priority review of lifileucel based on data from the phase 2 C-144-01 trial.

Lindsey Lyle, PA-C, MS, discusses how oncology nurses can work with their patients to determine if symptoms are related to their myeloproliferative neoplasm or another health condition.

Each month, Oncology Nursing News® takes a look back at our most popular stories.

Sarah Low RN, MSN, OCN, CMSRN; and Claudia Maldonado-Howell, RN, MSN, FNP, BS, CMSRN, highlight the importance of improving inpatient ambulation for transplant patients.

Tucatinib was first approved by the FDA for the treatment of patients with HER2-positive advanced unresectable or metastatic breast cancer in combination with trastuzumab and capecitabine on April 17, 2020.

For patients with myelofibrosis receiving pacritinib, spleen volume reduction was associated with improved overall survival.

Routine surface wipe testing helps identify specific areas of hazardous drug contamination and guide nurse leaders towards establishing improved protocols.

Mitazalimab and modified FOLFIRINOX produced a 57% objective response rate among patients with metastatic pancreatic ductal adenocarcinoma in the frontline setting.

Darcy Burbage, DNP, RN, AOCN, CBCN, shares which presentations from the 2023 ASCO Annual Meeting she found most important for oncology nurses.

Patients with breast and gastrointestinal cancers reported fewer hand-foot syndrome events following treatment with topical diclofenac gel.

Natasha Kormanik MSN, CRNP, FNP-BC, OCN, discusses accelerated vs regular approvals in hematologic oncology and how it applies to approved PI3K inhibitors.

The FDA has launched a priority review of repotrectinib based on data from the phase 1/2 TRIDENT-trial.

Phase 3 findings from the CLL12 trial support a watch-and-wait approach over systemic treatment with ibrutinib for patients with asymptomatic early-stage chronic lymphocytic leukemia.

FOLFOX was associated with lower rates or diarrhea and bowel dysfunction, but higher rates of fatigue, anxiety, nausea, and neuropathy, in data from the phase 2/3 PROSPECT trial.

The FDA has launched a priority review of fruquintinib as treatment for adult patients with previously treated metastatic colorectal cancer.

The phase 1/2 TRANSCEND CLL 004 trial met its primary end point by demonstrating that lisocabtagene maraleucel elicited responses in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.

Debi Fischer, MSW, BSN, BA, LCSW, RN, reviews key takeaways from a poster presented at the 2023 Oncology Nursing Society Congress.

What are the implications of new approvals for oncology nurses specializing in melanoma?

Talazoparib reduced the risk of progression or death by 55% in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations.

Brenda Martone MSN, ANP-BC, AOCNP, discusses the safety data from the phase 3 ARASENS trial.

The FDA has granted blinatumomab full approval for patients with minimal residual disease–positive B-cell acute lymphoblastic leukemia.

Wilderness therapy is a nontraditional form of therapy that uses components of exposure to outdoor activity and mental health treatment.

AnnMarie Walton, PhD, MPH, RN, OCN, CHES, FAAN, discusses the limitations of plastic-backed pads in inpatient oncology units.

Second-line treatment with CDK4/6 inhibition was associated with fewer toxicities and drug costs than frontline CDK4/6 inhibitor treatment—although progression-free survival and overall survival outcomes were similar.

The PARP inhibitor talazoparib has been approved in combination with enzalutamide for the treatment of adult patients with homologous recombination repair gene–mutated metastatic castration-resistant prostate cancer.

The rates of treatment discontinuation were higher with enzalutamide and apalutamide than with darolutamide for patients with non-metastatic castration resistant prostate cancer.

Lauren Mahon, MSN, FNP-BC, outlines nursing considerations with approved PARP inhibitors.